Cargando…

Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients

Background: Active Vitamin D analogues are used clinically for prevention and treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. Nutritional vitamin D supplementation is used for additional local parathyroid (PTH) suppression, with lower incidence of hypercalcemia and h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Jing-Quan, Hou, Yi-Chou, Zheng, Cai-Mei, Lu, Chien-Lin, Liu, Wen-Chih, Wu, Chia-Chao, Huang, Ming-Te, Lin, Yuh-Feng, Lu, Kuo-Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133095/ https://www.ncbi.nlm.nih.gov/pubmed/27827962 http://dx.doi.org/10.3390/nu8110708

Ejemplares similares

Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients
por: Zheng, Cai-Mei, et al.
Publicado: (2018)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
por: Fang, Li, et al.
Publicado: (2015)

The Influence of Different Cholecalciferol Supplementation Regimes on 25(OH) Cholecalciferol, Calcium and Parathyroid Hormone after Bariatric Surgery
por: Smelt, Hendrika J.M., et al.
Publicado: (2019)

Parathyroid hormone-producing cells exist in adipose tissues surrounding the parathyroid glands in hemodialysis patients with secondary hyperparathyroidism
por: Kakuta, Takatoshi, et al.
Publicado: (2020)

Radioimmunoassay of Parathyroid Hormone in Primary Hyperparathyroidism
por: Buckle, R. M.
Publicado: (1968)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
por: Izquierdo, María Jesús, et al.
Publicado: (2012)

Parathyroid Hormone on Osteoprotegerin Levels in Patients with Primary Hyperparathyroidism
por: Okudan, Berna, et al.
Publicado: (2022)

Low Parathyroid Hormone Versus Secondary Hyperparathyroidism and Survival in Patients Undergoing Hemodialysis: A Propensity-Matched Analysis
por: Guo, Wang, et al.
Publicado: (2022)

The value of intraoperative parathyroid hormone monitoring in patients with primary hyperparathyroidism and varying baseline parathyroid hormone levels
por: Hargitai, Lindsay, et al.
Publicado: (2022)

Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid and aorta of uremic rats
por: Ritter, Cynthia S., et al.
Publicado: (2015)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

Recurrence hyperparathyroidism caused by synchronous parathyroid carcinoma and parathyromatosis in a patient with long-term hemodialysis
por: Yang, Jun, et al.
Publicado: (2023)

Association between neutrophil-to-lymphocyte ratio and parathyroid hormone in patients with primary hyperparathyroidism
por: Lam, Hung-Bun, et al.
Publicado: (2018)

Evaluation of Postural Parathyroid Hormone Change in Patients with Primary Hyperparathyroidism
por: Aydin, Cevdet, et al.
Publicado: (2014)

Clinical usefulness of intraoperative parathyroid hormone monitoring for primary hyperparathyroidism
por: Paek, Se Hyun, et al.
Publicado: (2018)

The Effect of Vitamin C on Parathyroid Hormone in Patients on Hemodialysis With Secondary Hyperparathyroidism: A Double Blind, Placebo-Controlled Study
por: Biniaz, Vajihe, et al.
Publicado: (2013)

Hemodialysis patients with low serum parathyroid hormone levels have a poorer prognosis than those with secondary hyperparathyroidism
por: Yu, Yue, et al.
Publicado: (2020)

Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol
por: Oliva-Damaso, Elena, et al.
Publicado: (2016)

Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis
por: Liu, Yang, et al.
Publicado: (2019)

Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
por: Hansen, Ditte, et al.
Publicado: (2009)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD
por: Lu, Chien-Lin, et al.
Publicado: (2018)

Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients
por: Liao, Chia-Te, et al.
Publicado: (2021)

Minimally invasive parathyroidectomy with or without intraoperative parathyroid hormone for primary hyperparathyroidism
por: Kim, Hyun Gu, et al.
Publicado: (2015)

Intraoperative Parathyroid Hormone Monitoring in the Surgical Management of Sporadic Primary Hyperparathyroidism
por: Khan, Zahra F., et al.
Publicado: (2019)

The Importance of Correlation between Aldosterone and Parathyroid Hormone in Patients with Primary Hyperparathyroidism
por: Milicic Stanic, Branka, et al.
Publicado: (2022)

Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperparathyroidism in a haemodialysis patient
por: Cozzolino, Mario, et al.
Publicado: (2008)

Author Correction: Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients
por: Liao, Chia-Te, et al.
Publicado: (2022)

Use of intraoperative parathyroid hormone measurements during parathyroidectomy to predict postoperative parathyroid hormone levels in patients with renal hyperparathyroidism: meta-analysis
por: van Beek, Dirk-Jan, et al.
Publicado: (2022)

Efficacy of intraoperative parathyroid hormone monitoring to predict success of parathyroidectomy for secondary hyperparathyroidism
por: Kim, Woo Young, et al.
Publicado: (2012)

Preoperative Localization and Intraoperative Parathyroid Hormone Assay in Korean Patients with Primary Hyperparathyroidism
por: Cho, Eirie, et al.
Publicado: (2014)

Importance of Parathyroid Hormone Needle Aspiration Washout in Adenoma Localization in Primary Hyperparathyroidism
por: Pekkolay, Zafer, et al.
Publicado: (2019)

Is intraoperative parathyroid hormone monitoring necessary in symptomatic primary hyperparathyroidism with concordant imaging?
por: Nair, C. Gopalakrishnan, et al.
Publicado: (2016)

Interpretation of intraoperative parathyroid hormone monitoring according to the Rome criterion in primary hyperparathyroidism
por: Graceffa, Giuseppa, et al.
Publicado: (2022)

Effectiveness and Safety of Ultrasound-Guided Local Paricalcitol Injection in Treating Secondary Hyperparathyroidism in ESRD: A Retrospective Study
por: Xie, Shuqin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o95ndc575blhmp3ggk0mpngp9c